Skip to main content
Roquefort Therapeutics plc (LON:ROQ)
London flag London · Delayed Price · Currency is GBP · Price in GBX
0.975
-0.075 (-7.14%)
Mar 6, 2026, 4:35 PM GMT

Roquefort Therapeutics Income Statement

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
--0.2-0
Other Revenue
----0
Revenue
--0.2-0
Cost of Revenue
-0.02--0.01
Gross Profit
--0.020.2--0.01
Selling, General & Admin
0.750.941.511.310.38
Research & Development
0.180.150.620.320
Operating Expenses
0.931.12.131.630.38
Operating Income
-0.93-1.12-1.93-1.63-0.38
Interest Expense
-0.05-0.04-0--
Interest & Investment Income
--0--
Other Non Operating Income (Expenses)
-0.06-0.05---0.14
EBT Excluding Unusual Items
-1.04-1.21-1.93-1.63-0.52
Merger & Restructuring Charges
-----0.17
Pretax Income
-1.04-1.21-1.93-1.63-0.69
Income Tax Expense
-0.16-0.24-0.19-0.02-
Net Income
-0.88-0.97-1.74-1.62-0.69
Net Income to Common
-0.88-0.97-1.74-1.62-0.69
Shares Outstanding (Basic)
13913013010325
Shares Outstanding (Diluted)
13913013010325
Shares Change (YoY)
4.18%-25.66%318.92%-
EPS (Basic)
-0.01-0.01-0.01-0.02-0.03
EPS (Diluted)
-0.01-0.01-0.01-0.02-0.03
Free Cash Flow
-0.65-0.78-1.79-1.58-0.39
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.02
Gross Margin
--100.00%--
Operating Margin
---966.82%--60121.98%
Profit Margin
---872.27%--108018.05%
Free Cash Flow Margin
---893.79%--60851.65%
EBITDA
-0.93-1.11-1.93--
D&A For EBITDA
0.010.010--
EBIT
-0.93-1.12-1.93-1.63-0.38
Source: S&P Capital IQ. Standard template. Financial Sources.